Literature DB >> 7783538

Viridans streptococcal bacteraemia in patients with neutropenia.

P Richard1, G Amador Del Valle, P Moreau, N Milpied, M P Felice, T Daeschler, J L Harousseau, H Richet.   

Abstract

Viridans streptococcal bacteraemia is frequent in neutropenic patients. 25 neutropenic patients with viridans streptococcal bacteraemia were compared with 64 control patients. Exposure to repeated chemotherapy or cytarabine were independent risk-factors for streptococcal bacteraemia. The use of carboxyureidopenicillins and a stay in laminar-airflow rooms were protective. In a further cohort study of 49 patients, oral streptococci with the same ribotype as blood isolates were recovered from all 7 bacteraemic patients. The oral cavity is a portal of entry for viridans streptococci bacteraemia in neutropenic patients, especially after oral mucosal damage induced by repeated chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7783538     DOI: 10.1016/s0140-6736(95)90117-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  17 in total

1.  PCR-Based methods for genotyping viridans group streptococci.

Authors:  S Alam; S R Brailsford; R A Whiley; D Beighton
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

2.  Chemotherapy-induced oral mucositis and associated infections in a novel organotypic model.

Authors:  T Sobue; M Bertolini; A Thompson; D E Peterson; P I Diaz; A Dongari-Bagtzoglou
Journal:  Mol Oral Microbiol       Date:  2018-02-20       Impact factor: 3.563

3.  Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiologic analysis of 50 cases.

Authors:  Xiang Y Han; Mallika Kamana; Kenneth V I Rolston
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

4.  E test versus agar dilution for antimicrobial susceptibility testing of viridans group streptococci.

Authors:  S J Rosser; M J Alfa; S Hoban; J Kennedy; G K Harding
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

Review 5.  Intestinal microbiome changes and stem cell transplantation: Lessons learned.

Authors:  Ying Taur
Journal:  Virulence       Date:  2016-11-16       Impact factor: 5.882

Review 6.  The intestinal microbiota and susceptibility to infection in immunocompromised patients.

Authors:  Ying Taur; Eric G Pamer
Journal:  Curr Opin Infect Dis       Date:  2013-08       Impact factor: 4.915

7.  Mannosidase production by viridans group streptococci.

Authors:  K A Homer; G Roberts; H L Byers; E Tarelli; R A Whiley; J Philpott-Howard; D Beighton
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

8.  Comparison of activities of broad-spectrum beta-lactam compounds against 1,128 gram-positive cocci recently isolated in cancer treatment centers.

Authors:  D J Diekema; S L Coffman; S A Marshall; M L Beach; K V Rolston; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

9.  Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patients.

Authors:  H Wisplinghoff; R R Reinert; O Cornely; H Seifert
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

10.  Genotyping by amplified fragment length polymorphism analysis reveals persistence and recurrence of infection with Streptococcus anginosus group organisms.

Authors:  Jan A Jacobs; Jeroen H T Tjhie; Monique G J Smeets; Corrie S Schot; Leo M Schouls
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.